Molecular Partners AG
MOLN
Κατάταξη σε μετοχές
#19462
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Τιμή μετοχής
$3.99
Κεφαλαιοποίηση
$152.94M
Αλλαγή (1 ημέρα)
0.33%
Αλλαγή (1 έτος)
15.06%
Χώρα
CH
Εμπόριο Molecular Partners AG (MOLN)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του Molecular Partners AG(MOLN)
Κεφαλαιοποίηση: $152.94M
Μέχρι το October 2026, η Molecular Partners AG έχει χρηματιστηριακή αξία $152.94M. Αυτό καθιστά τη Molecular Partners AG την 19462nd πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Molecular Partners AG από 2016 έως 2026
MOLN σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για MOLN | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$134,514
$153.94M
|
$5.153T | +3,347,075.03% | ||
|
$130,311
$153.94M
|
$4.992T | +3,242,483.96% | ||
|
$108,656
$153.94M
|
$4.162T | +2,703,647.97% | ||
|
$102,709
$153.94M
|
$3.934T | +2,555,652.84% | ||
|
$74,022.56
$153.94M
|
$2.835T | +1,841,839.92% |
